Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
2024年2月24日 - 7:35AM
Grant of Restricted Stock Units to Management and Employees and
Grant of Warrants to Employees in Genmab
Company Announcement
COPENHAGEN, Denmark; February 23, 2024 –
Genmab A/S (Nasdaq: GMAB) announced today
that the board decided to grant
418,646 restricted stock units to members of management and
employees of the company as well as the company's subsidiaries and
316,899 warrants to employees of the company and the company's
subsidiaries.
Each restricted stock unit is awarded cost-free and provides the
owner with a conditional right to receive one share in Genmab A/S
of nominally DKK 1. The vesting of the restricted stock units
granted to the members of executive management will, with the
exception of deferred annual cash bonus, be subject to forward
looking performance criteria and consequently represent the maximum
opportunity available if the performance targets have been
significantly exceeded. The fair value of each restricted stock
unit is equal to the closing market price on the date of grant of
one Genmab A/S share, DKK 2,013.
The restricted stock units will vest on the first banking day of
the month following a period of three years from the date of grant.
Furthermore, the restricted stock units are subject to vesting
conditions set out in the restricted stock unit program adopted by
the Board of Directors. Information concerning Genmab’s restricted
stock unit program can be found on www.genmab.com under Investors
> Governance > Compensation > Restricted Stock
Units.
The exercise price for each warrant is DKK 2,013. Each warrant
is awarded cost-free and entitles the owner to subscribe one share
of nominally DKK 1 subject to payment of the exercise price. By
application of the Black-Scholes formula, the fair value of each
warrant can be calculated as DKK 652.81.
The warrants vest three years after the grant date, and all
warrants expire at the seventh anniversary of the grant date. The
new warrants have been granted on the terms and conditions set out
in the warrant program adopted by the Board of Directors on
February 23, 2021. Information concerning Genmab’s warrant schemes
can be found on www.genmab.com under Investors > Governance >
Compensation > Warrants.
About Genmab Genmab is an international
biotechnology company with a core purpose guiding its unstoppable
team to strive towards improving the lives of patients through
innovative and differentiated antibody therapeutics. For more than
20 years, its passionate, innovative and collaborative team has
invented next-generation antibody technology platforms and
leveraged translational research and data sciences, which has
resulted in a proprietary pipeline including bispecific T-cell
engagers, next-generation immune checkpoint modulators, effector
function enhanced antibodies and antibody-drug conjugates. To help
develop and deliver novel antibody therapies to patients, Genmab
has formed 20+ strategic partnerships with biotechnology and
pharmaceutical companies. By 2030, Genmab’s vision is to transform
the lives of people with cancer and other serious diseases with
Knock-Your-Socks-Off (KYSO™) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S. and Tokyo, Japan. For more information, please visit
Genmab.com and follow us on Twitter.com/Genmab.
Contact:
Marisol Peron, Senior Vice President, Communications and Corporate
AffairsT: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor RelationsT: +45
3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements.
The words “believe”, “expect”, “anticipate”, “intend” and “plan”
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors included in
Genmab’s most recent Annual Report on Form 20-F and other filings
with the U.S. Securities and Exchange Commission (SEC), which are
available at www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Company
Announcement nor to confirm such statements to reflect subsequent
events or circumstances after the date made or in relation to
actual results, unless required by law. Genmab A/S and/or its
subsidiaries own the following trademarks: Genmab®; the Y-shaped
Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®;
HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
Company Announcement no. 09 CVR no. 2102 3884 LEI Code
529900MTJPDPE4MHJ122
Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark
- 240223_CA09_Warrant and RSU Grant
Genmab AS (TG:GE9)
過去 株価チャート
から 5 2024 まで 6 2024
Genmab AS (TG:GE9)
過去 株価チャート
から 6 2023 まで 6 2024